Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Watchlist
Price: 246.46 USD -0.14%
Market Cap: 31.8B USD
Have any thoughts about
Alnylam Pharmaceuticals Inc?
Write Note

Relative Value

The Relative Value of one ALNY stock under the Base Case scenario is 270.89 USD. Compared to the current market price of 246.46 USD, Alnylam Pharmaceuticals Inc is Undervalued by 9%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALNY Relative Value
Base Case
270.89 USD
Undervaluation 9%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
79
vs Industry
38
Median 3Y
19.2
Median 5Y
26.5
Industry
7.7
Forward
13.9
vs History
vs Industry
Median 3Y
-24.6
Median 5Y
-22.3
Industry
22.2
Forward
-129.4
vs History
7
vs Industry
1
Median 3Y
-30.4
Median 5Y
-30.4
Industry
22.3
vs History
vs Industry
0
Median 3Y
-43.8
Median 5Y
-35.7
Industry
25.5
vs History
3
vs Industry
Median 3Y
-86.5
Median 5Y
10.8
Industry
2.5
vs History
79
vs Industry
33
Median 3Y
18.3
Median 5Y
24.3
Industry
7.8
Forward
13.1
vs History
79
vs Industry
27
Median 3Y
22.4
Median 5Y
29
Industry
9
vs History
vs Industry
Median 3Y
-31.1
Median 5Y
-26.7
Industry
3.9
Forward
-377
vs History
vs Industry
Median 3Y
-29.3
Median 5Y
-25.1
Industry
3.6
Forward
-185.2
vs History
7
vs Industry
1
Median 3Y
-27.7
Median 5Y
-27.7
Industry
5.2
vs History
3
vs Industry
1
Median 3Y
-26
Median 5Y
-24.8
Industry
3.3
vs History
9
vs Industry
13
Median 3Y
17.7
Median 5Y
14.5
Industry
4.6

Multiples Across Competitors

ALNY Competitors Multiples
Alnylam Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
31.8B USD 15.2 -95.6 -227.4 -159.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 888 840.5 -180 080 -218 674.5 -216 179.2
US
Abbvie Inc
NYSE:ABBV
314.4B USD 5.7 61.9 15.4 23.7
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117B USD 11 -243 24.2 25.5
US
Gilead Sciences Inc
NASDAQ:GILD
112.5B USD 4 892.3 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 859.4 -474.5 -516.7 -502.9
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.3B USD 6 17.7 16.1 17.9
US
Seagen Inc
F:SGT
39.3B EUR 17.9 -54.9 -59 -53.2
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.6 -130.6 -105.1 -76.6
P/E Multiple
Earnings Growth
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Average P/E: 208.4
Negative Multiple: -95.6
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 080 N/A
US
Abbvie Inc
NYSE:ABBV
61.9
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -243
42%
US
Gilead Sciences Inc
NASDAQ:GILD
892.3
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -474.5 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.9 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -130.6 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Average EV/EBITDA: 17.2
Negative Multiple: -227.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 674.5 N/A
US
Abbvie Inc
NYSE:ABBV
15.4
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.7 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.1 N/A
EV/EBIT Multiple
EBIT Growth
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Average EV/EBIT: 22.6
Negative Multiple: -159.8
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 179.2 N/A
US
Abbvie Inc
NYSE:ABBV
23.7
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -502.9 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.6 N/A

See Also

Discover More
Back to Top